Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15093441 | 0.92 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2CES2ACHECES1 | |
| SCHEMBL10272118 | 0.88 | PTGDR2 (0.36) | ALDH1A1SMN1; SMN2KDM4ELMNAMAPT | |
| SCHEMBL1699561 | 0.86 | KDM4E (0.40) | ALDH1A1SMN1; SMN2CES2ACHECES1 | |
| SCHEMBL10272178 | 0.84 | — | — | |
| SCHEMBL15093188 | 0.83 | CES2 (0.35) | ALDH1A1SMN1; SMN2CES2ACHECES1 | |
| SCHEMBL1699585 | 0.82 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2CES2ACHECES1 | |
| SCHEMBL1699288 | 0.81 | HTT (0.34) | ALDH1A1CES2ACHECES1NPSR1 | |
| SCHEMBL1699421 | 0.80 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL1699353 | 0.80 | SMN1; SMN2 (0.39) | ALDH1A1SMN1; SMN2CES2ACHECES1 | |
| SCHEMBL13734112 | 0.76 | PTPN1 (0.30) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588450-B1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES INC (US) | 2017-05-24 | — | — | EP | disclosed |
| EP-2588450-B1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES INC (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9284323-B2 | Naphthalene acetic acid derivatives against HIV infection | GILEAD SCIENCES, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9284323-B2 | Naphthalene acetic acid derivatives against HIV infection | GILEAD SCIENCES, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9102614-B2 | Naphth-2-ylacetic acid derivatives to treat AIDS | GILEAD SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102614-B2 | Naphth-2-ylacetic acid derivatives to treat AIDS | GILEAD SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102614-B2 | Naphth-2-ylacetic acid derivatives to treat AIDS | GILEAD SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2013103738-A1 | NAPTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| WO-2013103738-A1 | NAPTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| EP-2588450-A1 | NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS | Gilead Sciences, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012003497-A1 | NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003497-A1 | NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | NFATC1, ACIN1, NAAA | ALDH1A1 114/4885SMN1; SMN2 2614/4885CES2 1780/4885 |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | NFATC1, AADAT, ACAT1 | ALDH1A1 528/4885SMN1; SMN2 2881/4885CES2 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.